These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6848294)

  • 1. Urine and plasma propranolol.
    Andreasen F; Jakobsen P; Kornerup HJ; Pedersen EB; Pedersen OL
    Clin Pharmacol Ther; 1983 Jan; 33(1):10-8. PubMed ID: 6848294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in blood chemistry in hypertensive patients during propranolol therapy.
    Andreasen F; Jakobsen P; Kornerup HJ; Pedersen EB; Pedersen OL; Weeke J
    Br J Clin Pharmacol; 1984 Mar; 17(3):265-71. PubMed ID: 6712860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.
    Wong L; Nation RL; Chiou WL; Mehta PK
    Br J Clin Pharmacol; 1979 Aug; 8(2):163-7. PubMed ID: 486291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.
    Tiula E; Tallgren LG; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):545-52. PubMed ID: 3429058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of a new patient compliance index using plasma propranolol levels.
    Caldwell JR; Frade PD; Reddy PJ; Mayer JH; Kelly AR
    J Chronic Dis; 1984; 37(9-10):689-98. PubMed ID: 6501541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of drug concentration measurements in studies of the therapeutic response to propranolol.
    Chidsey C; Pine M; Favrot L; Smith S; Leonetti G; Morselli P; Zanchetti A
    Postgrad Med J; 1976; 52 Suppl 4():26-32. PubMed ID: 967771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in drug free fraction during alcohol withdrawal.
    Sandor P; Naranjo CA; Khouw V; Sellers EM
    Br J Clin Pharmacol; 1983 Apr; 15(4):481-6. PubMed ID: 6849785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Propranolol binding with plasma proteins and erythrocytes].
    Gneushev ET; Mamedov TSh; Gneusheva IA; Sivkov II
    Farmakol Toksikol; 1991; 54(1):55-7. PubMed ID: 1860502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massive propranolol metabolite retention during maintenance hemodialysis.
    Stone WJ; Walle T
    Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between plasma propranolol concentration and relief of essential tremor.
    Jefferson D; Jenner P; Marsden CD
    J Neurol Neurosurg Psychiatry; 1979 Sep; 42(9):831-7. PubMed ID: 501384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid, and p-hydroxypropranolol in human plasma and urine.
    Garceau Y; Davis I; Hasegawa J
    J Pharm Sci; 1978 Jun; 67(6):826-31. PubMed ID: 660467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total and free propranolol levels in sensitive and resistant patients.
    Steinberg SF; Bilezikian JP
    Clin Pharmacol Ther; 1983 Feb; 33(2):163-71. PubMed ID: 6822029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of propranolol and 4-hydroxy-propranolol at steady-state in neurological patients: intersubject and intrasubject correlations with dose.
    Albani F; Riva R; Baldrati A; Cortelli P; Perucca E; Procaccianti G; Baruzzi A
    Int J Clin Pharmacol Res; 1984; 4(1):19-23. PubMed ID: 6469429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma binding and the affinity of propranolol for a beta receptor in man.
    McDevitt DG; Frisk-Holmberg M; Hollifield JW; Shand DG
    Clin Pharmacol Ther; 1976 Aug; 20(2):152-7. PubMed ID: 947650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects.
    Vorobioff J; Picabea E; Gamen M; Villavicencio R; Bordato J; Bessone F; Tanno H; Palazzi J; Sarano H; Pozzoli L
    Hepatology; 1993 Sep; 18(3):477-84. PubMed ID: 8359793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and gender influence the stereoselective pharmacokinetics of propranolol.
    Gilmore DA; Gal J; Gerber JG; Nies AS
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1181-6. PubMed ID: 1602383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism by which hydralazine increases propranolol bioavailability.
    Schneck DW; Vary JE
    Clin Pharmacol Ther; 1984 Apr; 35(4):447-53. PubMed ID: 6705442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-methylated catechol-like metabolites of propranolol in man.
    Walle T; Conradi EC; Walle UK; Gaffney TE
    Drug Metab Dispos; 1978; 6(4):481-7. PubMed ID: 28930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.